NASDAQ:IRMD - Iradimed Stock Price, News, & Analysis

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

Iradimed announced that its Board of Directors has approved a stock repurchase program on Sunday, June 4th 2017, which authorizes the company to repurchase $8,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

Iradimed Corp (NASDAQ:IRMD) released its quarterly earnings data on Tuesday, October, 30th. The medical equipment provider reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The medical equipment provider had revenue of $7.62 million for the quarter, compared to the consensus estimate of $7.43 million. Iradimed had a return on equity of 11.72% and a net margin of 16.59%. View Iradimed's Earnings History.

Iradimed is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for Iradimed.

Iradimed issued an update on its FY 2018 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of $0.50-0.51 for the period, compared to the Thomson Reuters consensus estimate of $0.47. The company issued revenue guidance of $30-30.2 million, compared to the consensus revenue estimate of $30.23 million.Iradimed also updated its Q4 2018 guidance to $0.12-0.13 EPS.

1 brokers have issued 1 year price objectives for Iradimed's stock. Their predictions range from $35.00 to $35.00. On average, they anticipate Iradimed's share price to reach $35.00 in the next year. This suggests a possible upside of 36.0% from the stock's current price. View Analyst Price Targets for Iradimed.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

Headlines about IRMD stock have been trending very positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iradimed earned a news impact score of 3.9 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Iradimed saw a decrease in short interest in October. As of October 31st, there was short interest totalling 474,967 shares, a decrease of 31.7% from the October 15th total of 695,779 shares. Based on an average daily trading volume, of 146,238 shares, the short-interest ratio is presently 3.2 days. Currently, 10.1% of the company's shares are sold short. View Iradimed's Current Options Chain.

Some companies that are related to Iradimed include Orthofix Medical (OFIX), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Cerus (CERS), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SI-Bone (SIBN), Inovio Pharmaceuticals (INO), Anika Therapeutics (ANIK) and Orthopediatrics (KIDS).

Iradimed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.09%), Vanguard Group Inc. (2.29%), Renaissance Technologies LLC (1.82%), Mondrian Investment Partners LTD (1.09%), Cadence Capital Management LLC (0.68%) and EAM Investors LLC (0.57%). Company insiders that own Iradimed stock include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

IRMD stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Mondrian Investment Partners LTD, Russell Investments Group Ltd., Neuberger Berman Group LLC, Connors Investor Services Inc. and Macquarie Group Ltd.. Company insiders that have sold Iradimed company stock in the last year include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

IRMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., EAM Global Investors LLC, EAM Investors LLC, Walthausen & Co. LLC, Caxton Associates LP and Engineers Gate Manager LP. View Insider Buying and Selling for Iradimed.

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRMD stock can currently be purchased for approximately $25.74.

Iradimed has a market capitalization of $277.73 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Iradimed employs 83 workers across the globe.

The official website for Iradimed is http://www.iradimed.com.

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]